Sartorius Stedim Biotech Stock Performance
| SDMHF Stock | USD 206.00 2.30 1.10% |
The entity has a beta of -0.41, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Sartorius Stedim are expected to decrease at a much lower rate. During the bear market, Sartorius Stedim is likely to outperform the market. At this point, Sartorius Stedim Biotech has a negative expected return of -0.17%. Please make sure to validate Sartorius Stedim's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Sartorius Stedim Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Sartorius Stedim Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's technical indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 59.8 M | |
| Total Cashflows From Investing Activities | -465.2 M | |
| Free Cash Flow | 696 M |
Sartorius |
Sartorius Stedim Relative Risk vs. Return Landscape
If you would invest 23,300 in Sartorius Stedim Biotech on April 30, 2025 and sell it today you would lose (2,700) from holding Sartorius Stedim Biotech or give up 11.59% of portfolio value over 90 days. Sartorius Stedim Biotech is currently producing negative expected returns and takes up 2.5813% volatility of returns over 90 trading days. Put another way, 23% of traded pink sheets are less volatile than Sartorius, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Sartorius Stedim Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sartorius Stedim's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Sartorius Stedim Biotech, and traders can use it to determine the average amount a Sartorius Stedim's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0645
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SDMHF |
Estimated Market Risk
| 2.58 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sartorius Stedim is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sartorius Stedim by adding Sartorius Stedim to a well-diversified portfolio.
Sartorius Stedim Fundamentals Growth
Sartorius Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Sartorius Stedim, and Sartorius Stedim fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sartorius Pink Sheet performance.
| Return On Equity | 0.33 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 32.97 B | |||
| Shares Outstanding | 92.17 M | |||
| Price To Earning | 60.34 X | |||
| Price To Book | 13.58 X | |||
| Price To Sales | 9.62 X | |||
| Revenue | 2.89 B | |||
| EBITDA | 798.67 M | |||
| Cash And Equivalents | 161.7 M | |||
| Cash Per Share | 1.75 X | |||
| Total Debt | 521.07 M | |||
| Debt To Equity | 0.50 % | |||
| Book Value Per Share | 24.67 X | |||
| Cash Flow From Operations | 695.97 M | |||
| Earnings Per Share | 7.94 X | |||
| Total Asset | 3.95 B | |||
About Sartorius Stedim Performance
By analyzing Sartorius Stedim's fundamental ratios, stakeholders can gain valuable insights into Sartorius Stedim's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sartorius Stedim has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sartorius Stedim has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. Sartorius Stedim operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 10409 people.Things to note about Sartorius Stedim Biotech performance evaluation
Checking the ongoing alerts about Sartorius Stedim for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Sartorius Stedim Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sartorius Stedim generated a negative expected return over the last 90 days | |
| About 74.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Sartorius Stedim's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sartorius Stedim's stock is overvalued or undervalued compared to its peers.
- Examining Sartorius Stedim's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sartorius Stedim's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sartorius Stedim's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sartorius Stedim's pink sheet. These opinions can provide insight into Sartorius Stedim's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sartorius Pink Sheet analysis
When running Sartorius Stedim's price analysis, check to measure Sartorius Stedim's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sartorius Stedim is operating at the current time. Most of Sartorius Stedim's value examination focuses on studying past and present price action to predict the probability of Sartorius Stedim's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sartorius Stedim's price. Additionally, you may evaluate how the addition of Sartorius Stedim to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |